Volume 16, Issue 6 pp. 739-746
Original Article

Long-term outcome of biopsy-proven lupus nephritis in Iran

Alimohammad Fatemi

Corresponding Author

Alimohammad Fatemi

Department of Rheumatology, Alzahra Hospital, Isfahan University of Medical Sciences, Isfahan, Iran

*Correspondence: Assistant Professor Alimohammad Fatemi, Department of Rheumatology, Alzahra Hospital, Isfahan University of Medical Sciences, Isfahan, Iran 8174675731.

Email: [email protected]

Search for more papers by this author
Mehdi Kazemi

Mehdi Kazemi

Department of Internal Medicine, Alzahra Hospital, Isfahan University of Medical Sciences, Isfahan, Iran

Search for more papers by this author
Zahra Sayedbonakdar

Zahra Sayedbonakdar

Department of Rheumatology, Alzahra Hospital, Isfahan University of Medical Sciences, Isfahan, Iran

Search for more papers by this author
Ziba Farajzadegan

Ziba Farajzadegan

Department of Community Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

Search for more papers by this author
Hadi Karimzadeh

Hadi Karimzadeh

Department of Rheumatology, Alzahra Hospital, Isfahan University of Medical Sciences, Isfahan, Iran

Search for more papers by this author
Mahdi Moosavi

Mahdi Moosavi

Department of Internal Medicine, Alzahra Hospital, Isfahan University of Medical Sciences, Isfahan, Iran

Search for more papers by this author
First published: 25 November 2013
Citations: 10

Abstract

Introduction

This study was conducted to evaluate the survival of patients with lupus nephritis (LN) in two different lupus clinics in Iran.

Methods

This was a retrospective cohort study covering 82 patients diagnosed with biopsy-proven LN hospitalized between 1994 until 2010. Demographic, clinical, laboratory, therapeutic and end-point data were collected. Renal biopsies were categorized according to the 2004 classification of the International Society of Nephrology/Renal Pathology Society (ISN/RPS). Survival plots, univariate and multivariate Cox regression analyses were applied.

Results

Female/male ratio was 65/17. Mortality rate was 6.1% (five patients). Fifty-five (67%), 18 (22%), and four (4.9%) patients had complete/partial remission, chronic renal failure (CRF) and end-stage renal disease (ESRD), respectively. Renal biopsies showed 0, three (3.7%), 18 (22%), 58 (70.7%), two (2.4%) and 0 patients with ISN/RPS classes I, II, III, IV, V and VI, respectively, and one patient (1.2%) with mixed class (IV and V). The 5, 10 and 15 year survival rates for living patients were 97%, 92% and 69%, respectively. When CRF, ESRD and death were considered as one category of poor patient outcome, the 5, 10 and 15 year survival rates for remission were 87%, 47% and 35%, respectively. Multivariate analysis demonstrated the following independent protectives against poor outcome: class II nephritis (hazards ratio [HR] = 0.67; 95% confidence interval [CI], 0.57–0.85), class III nephritis (HR = 0.002; 95% CI, 0–0.036) and time passed since SLE diagnosis (HR = 0.006; 95% CI, 0–0.1).

Conclusion

Survival rates of Iranian patients with LN were comparable with those of developed countries.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.